Synthesis of Polymerized Human Serum Albumin by Wang, Qi
  
Synthesis of Polymerized Human Serum Albumin 
 
 
Undergraduate Honors Thesis 
 
Presented in Partial Fulfillment of the Requirements for 
Graduation with Honors and Distinction 
at The Ohio State University 
 
 
By 
Qi Wang 
 
 
William G. Lowrie Department of Chemical and Biomolecular Engineering 
The Ohio State University 
Spring, 2011 
 
Oral Defense Committee Members: 
Andre F. Palmer, Advisor 
David Wood 
 
 
i 
 
 
 
 
 
 
 
Copyrighted by 
Qi Wang 
2011 
  
 
 
ii 
 
Abstract 
 
In the event where blood for transfusion is unavailable, plasma expanders are often used 
to treat patients with significant blood loss. The use of many plasma expanders is often 
limited by their undesirable side effects. Human serum albumin (HSA) has been an 
attractive plasma expander. However, despite it being an important component in the 
blood, it can increase the risk of mortality when administered to patients with increased 
vascular permeability, such as in victims of severe burn injury, septic shock and 
endothelial dysfunction. This is caused by HSA extravasation, where HSA in the blood 
leaks to the surrounding tissues. This harmful side effect of HSA extravasation can be 
greatly reduced if the molecular size of HSA is increased. In this study, HSA was non-
specifically cross-linked with glutaraldehyde. The polymerized HSA (PolyHSA) made 
was stabilized by a quenching reaction with NaBH4, and purified with diafiltration. The 
molecular weight and viscosity of the polymerized HSA increases with increasing cross-
link density, and the colloid osmotic pressure (COP) decreases with increasing cross-link 
density. Circular dichroism shows that the secondary structure of HSA is conserved after 
polymerization. Altogether, these results show that glutaraldehyde can effectively cross-
link HSA, significantly increase its molecular size, yielding a series of novel potential 
plasma expanders with high molecular weight and viscosity that prevent the harmful 
effects of HSA extravasation. 
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I. Introduction 
 
1. Background on Plasma Expanders 
When blood is lost, the immediate need is to stop the blood loss, and replace the 
lost volume. When blood for transfusion is unavailable, plasma expanders (PEs) are 
commonly used to treat patients with significant blood loss. Unlike blood transfusions, 
which increase blood’s oxygen carrying capacity by adding more red blood cells (RBCs), 
PEs increase the oxygen delivery of the remaining RBCs by restoring the circulatory 
volume and maintaining adequate blood flow. Normal human blood has a significant 
excess oxygen transport capability. Patients in their resting state can safely tolerate a very 
low hemoglobin concentration, about 50 g/L, compared to 150 g/L for the normal blood 
hemoglobin concentration1,2. The decrease in red blood cell concentration increases the 
shear rate, which stimulus the endothelium to signal the dilation of blood vessels, 
maintaining systemic oxygen delivery3.  
Effectiveness of PE to stay within the intravascular space depends on its colloid 
osmotic pressure (COP) and molecular size. Molecules smaller than 50 kDa in size are 
rapidly excreted out of the body via kidneys. These molecules are also susceptible for 
rapid diffusion to the surrounding tissue space4. Intravascular COP must be kept either 
above the capillary hydrostatic pressure or at least greater than 10 mm Hg to maintain 
sufficient blood flow5. Depending on COP and size of PE molecule, this typically 
requires more infused volume of PE than the volume that is actually needed. The amount 
of PE needs to be infused can be reduced by using PEs with larger molecular size or 
higher COP. The increase in colloid osmotic pressure causes fluids to transfer from the 
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tissue space into the circulatory system, increasing the circulatory volume. This increase 
in circulating blood volume stabilizes the patient by restoring microvascular blood flow 
and capillary perfusion6. 
 
2. Types of Plasma Expanders 
There are several types of PEs that are currently in use. For example, crystalloid-
based saline (0.9%), colloids like gelatin, dextran, hydroxyethyl starch, and human serum 
albumin7. However, the use of them many cause undesirable side effects.  
Crystalloids and colloids based solutions are the established procedure for 
primary volume replacement in patients with hemorrhagic shock8. Examples of 
crystalloid based solutions are dextrose and crystalloid-based saline (0.9%). Crystalloid 
based solutions are inexpensive, but their effectiveness lack endurance, and need to be 
continually supplied8. These solutions acts as free water after intravenous administration, 
and is quickly metabolized. They rapidly equilibrate between the intracellular and 
extracellular space. For every 100 mL of an intravenous infusion of saline solution, about 
three-quarters will pass into the interstitial space within the first hour, and only one-
quarter remains in the intravascular space. Only 5-7 mL remains in the intravascular 
space for every 100 mL of dextrose solutions infused5.  
Colloid derived plasma expanders can be based from either natural (human serum 
albumin), and synthetic (dextrans, hydroxyethyl starches) macromolecules. Since colloids 
are larger in size, their retention rate within the intravascular space is better than 
crystalloids. However, colloids may still leak out from capillaries to the surrounding 
tissue space, increasing the interstitial colloid osmotic pressure, which causes a negative 
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effect of increasing the fluid flux out from blood vessels5. Colloids like gelatins have 
poor volume expansion and may cause allergic reactions9. Other examples of colloid 
based PEs are Dextran and hydroxyethyl starch.  
Dextran is a complex, branched polysaccharide composed of chains of varying 
length.  Hydroxyethyl starch (HES) is a type of synthetic colloid derived from 
amylopectin. These types of PEs can remain effective for up to 24 hours5. Dextrans and 
hydroxyethyl starches have been shown to be able to restore circulatory volume and 
microvascular perfusion10,11. However, despite their benefits, the use of these types of 
PEs is limited by their negative impact on red blood cells aggregation, and acute renal 
failure12,13. Another disadvantage of hydroxyethyl starch solutions is that they contain 
molecules with a wide range of molecular weights, and the smaller molecules will be 
rapidly excreted from the body, decreasing its effectiveness5. 
Human serum albumin (HSA) is a type of naturally based colloid derived from 
donated blood, and the use of it as a PE has many advantages. It is naturally produced in 
the liver, makes up ~50% of the total plasma protein14, provides ~75% of the plasma’s 
COP15, and has been shown to be generally safe16. When administered, its duration of 
effectiveness within the intravascular space can be up to a day, and it persists within the 
body for about 20 days5. However, HSA has also been shown to increase the risk of 
morality in patients with severe burn injury and sepsis. This is likely due to HSA 
extravastion in patents with increased vascular permeability17,18. Extravasation of HSA 
can cause edema, reduce plasma COP, and expose tissues to toxins bound by HSA. 
 
3. Objectives and Experimental Summary 
 
 
4 
 
The objectives of this project are to produce a series of novel plasma expanders 
from HSA and glutaraldehyde, having high molecular weight, high viscosity, and low 
COP. Higher molecular weight PolyHSA can limit extravasation, a harmful effect of 
monomeric HSA PE in patents with increased vascular permeability19. Higher viscosity 
can induce vasodilation and increased microvascular perfusion20,21. Lower COP can 
control the volume expansion of PolyHSA to be within a safe level.  
In this study, HSA was polymerized with glutaraldehyde at glutaraldehyde to 
HSA molar ratios of 24:1, 60:1 and 94:1, and stabilized by a quenching reaction with 
NaBH4. The PolyHSA made was then purified with tangential flow filtration. Weight 
averaged molecular weight distribution, secondary structure, viscosity, and COP was 
measured to assess its potential as a novel plasma expander.  
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II. Background 
 
Payne et al. polymerized bovine serum albumin (BSA) with various 
concentrations of glutaraldehyde22. They showed that it is possible to increase the 
molecular size of BSA by reacting it with glutaraldehyde. However, is that study, a 
reducing agent, such as NaBH4, was not used to stabilize the polymerized BSA, making it 
susceptible to degradation back to free BSA. In a study done by Cabrales et al., HSA was 
covalently conjugated with polyethylene glycol (PEG), and was shown to exhibit a longer 
circulatory half-life and increased blood volume expansion function23. 
 Glutaraldehyde had previously been used to crosslink hemoglobin (Hb) to yield a 
large Hb-based oxygen carrier. There are two commercial glutaraldehyde cross-linked 
Hbs available24. HBOC-201 is a glutaraldehyd polymerized bovine Hb developed by 
Biopure Corp.Cambridge, MA, with an average molecular weight (MW) of 250 kDa. 
PolyHeme, developed by Northfield Labs, Evanston, IL, is a glutaraldehyde polymerized 
human Hb with an average MW of 150 kDa. Recently, HBOC-201 had shown promising 
results in phase III clinical trials25. 
Studies had shown that there are many benefits associated with the use of high 
viscosity PEs26,27.  The use of high-viscosity plasma expanders better maintain capillary 
perfusion and microvascular flow in extreme cases of hemorrhagic shock8. High viscosity 
plasma expanders also maintain the functional capillary density (FCD), making the use of 
them in patients with extreme anemia more desirable8.  FCD is the number of functional 
capillaries for passage of red blood cells per unit surface of tissue, and it has been found 
by Kerger et al. that this parameter is important in defining tissue survival28.  
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PolyHSA’s advantage of having higher viscosity and molecular weight, together 
with HSA’s benefit of being naturally prevalent in the blood, shows its potential of being 
a series of novel plasma expanders that prevents the harmful side effects of other types of 
PEs.  
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2. Materials 
AlbuminarVR -25 (HSA) was purchased from ABO Pharmaceuticals (San Diego, 
CA) at a concentration of 250 mg/mL. Glutaraldehyde (70 wt%) was purchased from 
Sigma Aldrich (Atlanta, GA). Other chemicals including NaBH4, NaCl, NaOH, HCl, 
KCN, sodium lactate, N-acetyl-L-cysteine, NaH2PO4, and Na2HPO4 were purchased from 
Fisher Scientific (Pittsburgh, PA). KrosFlow Research II tangential flow filtration (TFF) 
system and two 500 kDa hollow fiber (HF) filter modules were obtained from Spectrum 
Laboratories (Rancho Dominguez, CA). Those HF filters were made from polysulfone 
with a total membrane surface area of 615 cm2.  
 
3. PolyHSA Synthesis  
For synthesis of PolyHSA, 100 mL of HSA (250 mg/mL) was diluted to 25 
mg/mL with phosphate buffered saline (PBS) (1.42 gm Na2HPO4, 8.18 gm NaCl, and 
0.75 mg KCl per liter, pH = 7.4) up to a final volume of 1 L. Glutaraldehyde (70 wt%) 
was added to HSA solutions at the following molar ratios of glutaraldehyde to HSA: 24:1 
(HSA24), 60:1 (HSA60), and 94:1 (HSA94). The polymerization reaction was incubated at 
37oC for 3 hours, then quenched with 25 mL of 1 M sodium borohydride and incubated 
for an additional 30 minutes. 
 
4. PolyHSA Purification 
For purification of PolyHSA, diafiltration was used to eliminate the presence of 
free glutaraldehyde and other impurities in the final product, PolyHSA solutions were 
diafiltrated with 2 L of modified lactated Ringer’s buffer (115 mM NaCl, 4 mM KCl, 1.4 
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5. PolyHSA Characterization 
The increase of molecular weight (MW) of PolyHSA was shown by SDS-PAGE 
Analysis. The absolute MW distribution of PolyHSA solutions was measured using light 
scattering photometer. Circular Dichroism was used to compare the secondary structure 
of PolyHSA with HSA.  
Viscosity measurements of HSA/PolyHSA solutions were conducted in a 
cone/plate viscometer DV-II plus, with a cone spindle CPE-40 (Brookfield Engineering 
Laboratories, Middleboro, MA) at a shear rate of 160 s-1, and the COP of polyHSA was 
measured with a Wescor 4420 Colloid Osmometer (Wescor, Logan, UT). 
For Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
analysis, protein (25 μg) from each HSA/PolyHSA solution was mixed with Lammeli 
buffer (1:1 ratio), incubated at 95oC for 5 min, and ran on a polyacrylamide gel (12% 
resolving gel and 4% stacking gel) at 110 V for 1.5 hrs. The gel was then stained with 
Coomassie blue for ~12 hrs, destained with destaining solution (20% ethanol and 10% 
acetic acid), and visualized on a Gel Doc XR imaging system (BioRad Hercules,CA). 
 For measuring the absolute molecular weight distribution of HSA/PolyHSA 
solutions, light scattering instruments consisting of a size exclusion column 
(Ultrahydrogel linear column, 10 μm, 7.8x300 mm; Waters, Milford, MA) driven by a 
1200 HPLC pump (Agilent, Santa Clara, CA), controlled by Eclipse 2 software (Wyatt 
Technology, Santa Barbara, CA) connected in series to a DAWN Heleos (Wyatt 
Technology) light scattering photometer and an OptiLab Rex (Wyatt Technology) 
differential refractive index detector was used. The mobile phase consisted of 20 mM 
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phosphate buffer (pH 8.0), 100 ppm NaN3, and 0.2 M NaCl (Fisher Scientific) in HPLC 
grade water that was filtered through a 0.2 μm membrane filter. HSA and PolyHSA 
solutions were diluted to 1 mg/mL with the mobile phase, and 100 μL of the sample was 
injected into the column via a 1200 Autosampler (Agilent). All data were collected and 
analyzed using Astra 5.3 (Wyatt Technology) software. 
 Circular dichroism (CD) spectra were obtained on an AVIV Circular Dichroism 
Spectrophotometer Model 202 (Aviv Biomedical Lakewood, NJ). HSA and PolyHSA 
solutions were diluted with PBS to ~80 μg/mL. The cell temperature was maintained at 
25oC and each spectrum was averaged over three consecutive measurements taken at 1 
nm intervals from 200 to 250 nm.  
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IV. Results 
 
SDS-PAGE showing MW distribution of HSA/PolyHSA solutions is shown in 
Figure 3. The absolute MW distribution of HSA/PolyHSA solutions measured using size 
exclusion chromatography coupled with static light scattering is shown in Figure 4, and 
the weight averaged MW of HSA and PolyHSA solutions based on triplicate reactions is 
reported in Table 1. Circular Dichroism (CD) used to compare the secondary structure of 
PolyHSA solutions with HSA is shown in Figure 5. The viscosity of HSA/PolyHSA 
solutions, and the COP of PolyHSA solutions is shown in Table 2. 
 
1. SDS-PAGE Analysis 
Glutaraldehyde polymerized HSA produced a wide distribution of large MW 
molecules. Monomeric HSA used as control, shows a strong band at around 67 kDa, the 
literature reported HSA monomer MW, and several faint bands at lower MWs (degraded 
proteins). Each of the PolyHSA solutions displays intense broad bands above 100 kDa. It 
is evident that the MW of PolyHSA increases with increasing cross-link density. There 
are some polymerized HSA present in each of the PolyHSA solutions. However, the 
amount of HSA monomer decreases as the glutaraldehyde:HSA molar ratio (cross-link 
density) increases. 
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Sample Viscosity (cp) COP (mm Hg) 
HSA Control 1.4 42 
24:1 PolyHSA 1.6 22 
60:1 PolyHSA 11.2 4 
94:1 PolyHSA 15.2 1 
Table 2: Viscosity and COP of HSA and PolyHSA solutions at 10 g/dL. 
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V. Discussion 
 
1. Effects of Polymerization on MW and Secondary Structure 
SDS-PAGE analysis and light scattering results show that glutaraldehyde can be 
effectively used to polymerize HSA at cross-link densities of 24:1, 60:1, and 94:,1 to 
yield a solution of high MW polymers. As expected, increasing the cross-link density 
increases the weight averaged MW of the PolyHSA solution. The CD spectra show that 
the reaction of glutaraldehyde with HSA does not affect the secondary structure of HSA, 
so the protein does not unfold, preserving its functions, such as toxin binding. 
 
2. Effects of Polymerization on Viscosity and Colloid Osmotic Pressure  
The viscosities of PolyHSA solutions are higher than that of HSA at the same 
total protein concentration at 10 g/dL, Viscosity also increases as cross-link density 
increases. This is likely due to the large increase in the weight averaged MW of the 
PolyHSA solutions, which increases the frequency of molecular interactions between 
neighboring PolyHSA molecules, causing their viscosities to increase. 
COP of the PolyHSA solutions decreases with increasing cross-link density and is 
significantly lower than that of HSA. This significant reduction in COP is probably due 
to the fact that COP is primarily determined by the presence of unpolymerized HSA and 
small HSA polymers in solution. As cross-link density increases, PolyHSA molecules get 
larger, and the number of unreacted HSA decreases, which in turn reduces the COP.  
 
3. Effects of PE Viscosity 
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It has been believed that lowering blood viscosity leads to an overall health 
benefit by decreasing vascular resistance and heart workload31. However, on the contrary, 
PEs with high viscosity increases the shear stress of the blood vessel walls, which 
induces endothelial cells to produce nitric oxide (NO) that in turn dilates blood 
vessels32,33. NO is a critical regulator of vascular homeostasis and controls vascular 
relaxation34,35. This dilation in blood vessel makes oxygen transport to the sounding 
tissues easier and increases microvascular perfusion. High viscosity PEs can be used to 
preserve normal blood viscosity in cases of acute drop in blood volume36. 
In an animal study done by Tsai et al., it was shown that the use of a high 
viscosity, low COP PE allows a better maintenance of stable hemodynamic conditions in 
cases of extreme anima26. In that experiment, a high viscosity PE was used to increase the 
blood viscosity without simultaneously increasing the colloid oncotic pressure (COP) to 
viscosities beyond the normal blood viscosity. It was discovered that the high blood 
viscosity group had a significantly higher functional capillary density and an increase in 
blood flow.  
Studies have shown that the viscosity of a PE can be increased with increasing 
concentration26. However, there is a physiological limitation to this self-limiting 
approach. Increasing the PE concentration also increases the COP37. Since higher COP 
increases the amount of extravascular fluid being pulled into the intravascular space, this 
not only makes it harder to control the amount of PE needs to be infused, it also dilutes 
the blood, reducing the blood viscosity to a point lower than the desired value.  
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VI. Recommendations 
 
Despite the many benefits associated with the use of high viscosity PEs, 
especially in the treatment of extreme cases of hemorrhagic shock and anemia. High 
viscosity PEs also have negative effects. For example, increasing the blood viscosity will 
also rapidly increase vascular resistance, causing the heart workload to increase31. 
Therefore the use of high viscosity PolyHSA PEs should be leveraged with their negative 
effects.  
Because of PolyHSA’s high viscosity and low COP properties, it is recommended 
that PolyHSA to be formulated with HSA or other type of plasma expanders in cases 
where volume expansion is required. It can also be used to increase the viscosity of the 
blood while keeping the COP low, making it an ideal PE for the treatment of extreme 
anemia and extreme cases of hemorrhagic shock. Animal studies with glutaraldehyde 
cross-linked HSA could be used to determine its effects on functional capillary density, 
microvascular perfusion, and general recovery after hemorrhagic shock. 
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VI. Conclusions 
 
The results of this study show that glutaraldehyde can be used to produce a high 
MW HSA polymer with conserved secondary structure, high viscosity, and low COP. 
The large MW of PolyHSA should limit extravasation and its high viscosity should 
induce vasodilation and increased microvascular perfusion. The low COP may limit 
volume expansion of PolyHSA beyond the infused volume, but the large size of 
PolyHSA should ensure the effectiveness of the infused volume within the intravascular 
space.  
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